11.31

5.01% 0.5495

Regenxbio Inc (RGNX)

Overview News Price History Option Chain Financials Discussions Forecast

Regenxbio Inc stock is traded at $11.31, with a volume of 678.17K. It is up +5.01% in the last 24 hours and up +14.30% over the past month. Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.

Previous Close:

$10.77

Open:

$10.69

24h Volume:

678.17K

Relative Volume:

0.32

Market Cap:

$744.89M

Revenue:

$170.44M

Net Income/Loss:

$-193.88M

P/E Ratio:

-3.0139

EPS:

-3.7541

Net Cash Flow:

$-126.38M

1W Performance:

+8.49%

1M Performance:

+14.30%

6M Performance:

+40.60%

1Y Performance:

+28.17%

1-Day Range:

$10.53

$11.34

1-Week Range:

$10.15

$11.34

52-Week Range:

$5.455

$16.19

Regenxbio Inc Stock (RGNX) Company Profile

Name

Regenxbio Inc

Sector

Healthcare (1089)

Industry

Biotechnology (604)

Phone

240-552-8181

Address

9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD

Employee

371

Twitter

@REGENXBIO

Next Earnings Date

2026-08-06

Latest SEC Filings

RGNX's Discussions on Twitter

Compare RGNX vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RGNX Regenxbio Inc	11.28	710.63M	170.44M	-193.88M	-126.38M	-3.7541
VRTX Vertex Pharmaceuticals Inc	515.50	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	806.71	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	991.46	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	212.24	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	362.25	39.31B	5.76B	514.49M	1.10B	4.4813

Regenxbio Inc Stock (RGNX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-28-26	Resumed	Barclays	Overweight
Feb-11-25	Downgrade	Goldman	Buy → Neutral
Feb-07-25	Resumed	Raymond James	Outperform
Nov-15-24	Resumed	Morgan Stanley	Overweight
Oct-10-24	Resumed	Raymond James	Outperform
Jun-07-24	Initiated	Goldman	Buy
Mar-11-24	Initiated	H.C. Wainwright	Buy
Mar-08-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Mar-06-24	Upgrade	Leerink Partners	Market Perform → Outperform
Feb-21-24	Resumed	Raymond James	Outperform
Nov-01-23	Initiated	Stifel	Buy
Jun-02-23	Initiated	Robert W. Baird	Outperform
Jun-23-22	Initiated	Berenberg	Buy
Dec-15-21	Initiated	Wedbush	Neutral
Oct-19-21	Resumed	Morgan Stanley	Overweight
Jan-06-21	Upgrade	Raymond James	Outperform → Strong Buy
Dec-16-20	Initiated	UBS	Buy
Jun-25-20	Resumed	BofA/Merrill	Buy
May-13-20	Initiated	RBC Capital Mkts	Sector Perform
Aug-20-19	Upgrade	SVB Leerink	Underperform → Mkt Perform
Jun-18-19	Reiterated	Chardan Capital Markets	Buy
Jun-14-19	Resumed	Raymond James	Outperform
Jun-05-19	Reiterated	Chardan Capital Markets	Buy
Feb-25-19	Upgrade	Evercore ISI	In-line → Outperform
Feb-05-19	Upgrade	Raymond James	Outperform → Strong Buy
Dec-17-18	Reiterated	Chardan Capital Markets	Buy
Nov-08-18	Reiterated	BofA/Merrill	Neutral
Aug-08-18	Reiterated	Chardan Capital Markets	Buy
Jul-23-18	Downgrade	BofA/Merrill	Buy → Neutral
Jul-10-18	Reiterated	Chardan Capital Markets	Buy
May-09-18	Reiterated	Barclays	Overweight
Apr-09-18	Reiterated	Chardan Capital Markets	Buy
Mar-12-18	Downgrade	Evercore ISI	Outperform → In-line
Feb-13-18	Initiated	Mizuho	Neutral
Nov-09-17	Resumed	Morgan Stanley	Overweight

View All

Regenxbio Inc Stock (RGNX) Latest News

05:39 AM

RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review

05:39 AM

Aug 15, 2026

Walleye Capital LLC Invests $2.44 Million in REGENXBIO Inc. $RGNX - marketbeat.com

Aug 15, 2026

Aug 14, 2026

Regenxbio Stock Price Forecast. Should You Buy RGNX? - StockInvest.us

Aug 14, 2026

REGENXBIO (NASDAQ:RGNX) Rating Increased to Hold at Zacks Research - marketbeat.com

Aug 14, 2026

Assenagon Asset Management S.A. Has $2.03 Million Position in REGENXBIO Inc. $RGNX - marketbeat.com

Aug 14, 2026

Aug 13, 2026

FDA Commissioner Refers To Rare Disease Drug With Associated Morbidity: Analysts Are Divided If Makary Meant Regenxbio Or Uniqure’s Experimental Therapy - Stocktwits

Aug 13, 2026

Aug 12, 2026

(RGNX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily

Aug 12, 2026

HC Wainwright Has Pessimistic View of REGENXBIO Q3 Earnings - marketbeat.com

Aug 12, 2026

Aug 11, 2026

REGENXBIO’s Multi-Catalyst Setup Is Hard To Ignore (Rating Upgrade) (NASDAQ:RGNX) - Seeking Alpha

Aug 11, 2026

Regenxbio posts strong Q with 407% revenue grow... - Pluang

Aug 11, 2026

Aug 10, 2026

H.C. Wainwright lowers Regenxbio stock price target on equity offering By Investing.com - Investing.com UK

Aug 10, 2026

RGNX Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus

Aug 10, 2026

H.C. Wainwright lowers Regenxbio stock price target on equity offering - Investing.com

Aug 10, 2026

H.C. Wainwright Maintains Regenxbio(RGNX.US) With Buy Rating, Cuts Target Price to $23 - Moomoo

Aug 10, 2026

Dimensional Fund Advisors LP Increases Stock Position in REGENXBIO Inc. $RGNX - marketbeat.com

Aug 10, 2026

Aug 09, 2026

RGNX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review

Aug 09, 2026

RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds - The National Law Review

Aug 09, 2026